Cargando…

Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.

Two clinical studies were undertaken to study the toxicity profile and effects of interleukin-3 (rhIL-3) on chemotherapy-induced myelosuppression. Fifteen patients with recurrent ovarian carcinoma were treated with high dose carboplatin (800 mg m-2). All patients received 5.0 micrograms/kg/d rhIL-3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dercksen, M. W., Hoekman, K., ten Bokkel Huinink, W. W., Rankin, E. M., Dubbelman, R., van Tinteren, H., Wagstaff, J., Pinedo, H. M.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1993
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968723/ https://www.ncbi.nlm.nih.gov/pubmed/7692922

Ejemplares similares

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
por: Herben, V. M., et al.
Publicado: (1997)

Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
por: de Wit, R., et al.
Publicado: (1997)

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer
por: Terwogt, J M M, et al.
Publicado: (1999)

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.
por: de Wit, R., et al.
Publicado: (1998)

TGFβ restores hematopoietic homeostasis after myelosuppressive chemotherapy
por: Brenet, Fabienne, et al.
Publicado: (2013)

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients
por: Malingré, M M, et al.
Publicado: (2001)

Predictive Model of Chemotherapy-Induced Myelosuppression for Patients with Esophageal Cancer
por: Zheng, Ziming, et al.
Publicado: (2022)

Effects of Designer Hyper-Interleukin 11 (H11) on Hematopoiesis in Myelosuppressed Mice
por: Dams-Kozlowska, Hanna, et al.
Publicado: (2016)

Conventional myelosuppressive chemotherapy for non-haematological malignancy disrupts the intestinal microbiome
por: Papanicolas, Lito E., et al.
Publicado: (2021)

Lobular panniculitis after subcutaneous administration of interleukin-2 (IL-2), and its exacerbation during intravenous therapy with IL-2.
por: Baars, J. W., et al.
Publicado: (1992)

The effect of chemotherapy on subjective cognitive function in younger early-stage breast cancer survivors treated with chemotherapy compared to older patients
por: Gregorowitsch, M. L., et al.
Publicado: (2019)

The impact of the oral cavity in febrile neutropenia and infectious complications in patients treated with myelosuppressive chemotherapy
por: Zecha, Judith A. E. M., et al.
Publicado: (2019)

Oral topotecan: bioavailability and effect of food co-administration
por: Herben, V M M, et al.
Publicado: (1999)

Cutting the brakes on hematopoietic regeneration by blocking TGFβ to limit chemotherapy-induced myelosuppression
por: Brenet, Fabienne, et al.
Publicado: (2015)

Myelosuppression by sunitinib is flt-3 genotype dependent
por: van Erp, N P, et al.
Publicado: (2010)

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.
por: de Wit, R., et al.
Publicado: (1995)

The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients
por: Malingré, M M, et al.
Publicado: (2001)

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer
por: Helgason, H H, et al.
Publicado: (2006)

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
por: Kumar, R, et al.
Publicado: (2009)

Case Report: A Patient with COVID-19 under Myelosuppression Induced by Chemotherapy
por: Otsuka, Yuki, et al.
Publicado: (2020)

Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.
por: de Wit, R., et al.
Publicado: (1998)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma
por: Arends, J J, et al.
Publicado: (2005)

Two patients with a neuroendocrine tumour of the small intestine and paraneoplastic myasthenia gravis
por: Hermans, M A W, et al.
Publicado: (2014)

Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.
por: McLeod, H. L., et al.
Publicado: (1996)

Translational Modeling of Drug‐Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor
por: Collins, TA, et al.
Publicado: (2017)

Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously.
por: Honkoop, A. H., et al.
Publicado: (1996)

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks
por: Kerbusch, T, et al.
Publicado: (2004)

A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2.
por: Ogilvie, A. C., et al.
Publicado: (1994)

Highly sensitive and specific detection of P-glycoprotein function for haematological and solid tumour cells using a novel nucleic acid stain.
por: Broxterman, H. J., et al.
Publicado: (1997)

An evaluation of the factors that affect the health-related quality of life of children following myelosuppressive chemotherapy
por: Baggott, Christina R., et al.
Publicado: (2010)

Determinants of Myelosuppression in the Treatment of Non‐small Cell Lung Cancer with Cisplatin‐containing Chemotherapy
por: Matsui, Kaoru, et al.
Publicado: (1996)

Patterns of granulocyte colony–stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy
por: Gawade, Prasad L., et al.
Publicado: (2020)

Ginsenoside Rg3 for Chemotherapy-Induced Myelosuppression: A Meta-Analysis and Systematic Review
por: Pan, Linlin, et al.
Publicado: (2020)

Cancer Patients’ Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life
por: Epstein, Robert S, et al.
Publicado: (2021)

Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.
por: Sternberg, C. N., et al.
Publicado: (1994)

Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.
por: Brugnatelli, S., et al.
Publicado: (1996)

Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.
por: Elferink, F., et al.
Publicado: (1987)

bcl-2 gene enables rescue from in vitro myelosuppression (bone marrow cell death) induced by chemotherapy.
por: Kondo, S., et al.
Publicado: (1994)

Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.
por: Hanauske, A. R., et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_b68l7dg5mfn7pl4r8dqgopg8oc